Research map: Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate

Back to the article

Papers in this map

  1. Evolutionary-scale prediction of atomic-level protein structure with a language model · Zeming Lin · 2023 · 5594 citations · Cited by this paper
  2. NAStructuralDB : structural database to facilitate computational studies of molecular modeling and recognition of proteins with special focus on antibody–antigen interactions · 2026 · Related
  3. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) · Craig L. Leonardi · 2008 · 1876 citations · Cited by this paper
  4. Engineering of acidic pH-responsive anti-CD3 binding antibodies · 2026 · Related
  5. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) · Kim Alexander Papp · 2008 · 1365 citations · Cited by this paper
  6. Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutions · 2026 · Related
  7. Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma · ADIL I. DAUD · 2008 · 701 citations · Cited by this paper
  8. Balancing the extremes for antibody developability: hydrophobic and electrostatic germline framework signatures for CDR-loop compensation · 2026 · Related
  9. Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site · Jenny Boström · 2009 · 372 citations · Cited by this paper
  10. Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning · 2026 · Related
  11. A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies · Gabriele Schaefer · 2011 · 338 citations · Cited by this paper
  12. ASD: antigen-specific antibody database · 2026 · Related
  13. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. · Barbara Carnemolla · 1989 · 338 citations · Cited by this paper
  14. Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety · 2026 · Related
  15. Application of phage display to high throughput antibody generation and characterization · Darren J. Schofield · 2007 · 238 citations · Cited by this paper
  16. AbDist: a lightweight, distance-based model for antibody affinity prediction as an interpretable benchmark for machine learning models · 2026 · Related
  17. Identification of a third region of cell-specific alternative splicing in human fibronectin mRNA. · A. Gutman · 1987 · 132 citations · Cited by this paper
  18. Novel bispecific T-cell engagers overcoming acquired EGFR resistance · 2026 · Related
  19. A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma · Sarah Maria Rudman · 2011 · 110 citations · Cited by this paper
  20. JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy · 2026 · Related
  21. Human fibronectin extra domain B as a biomarker for targeted therapy in cancer · Relinde I. Y. Lieverse · 2020 · 56 citations · Cited by this paper
  22. Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade · Andrea T. Hooper · 2022 · 52 citations · Cited by this paper
  23. Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity · Luciano Santollani · 2024 · 49 citations · Cited by this paper
  24. A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors · Tiziano Ongaro · 2018 · 40 citations · Cited by this paper
  25. Intratumoral nanobody–IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice · Emi A. Lutz · 2022 · 32 citations · Cited by this paper
  26. A Two-in-One antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions · Chingwei V. Lee · 2014 · 31 citations · Cited by this paper
  27. Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer · Hirofumi Mikami · 2024 · 31 citations · Cited by this paper
  28. mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity · Christopher J. Nirschl · 2023 · 24 citations · Cited by this paper
  29. An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses · Eva Gutierrez · 2023 · 22 citations · Cited by this paper
  30. XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies · Ekta P. Patel · 2023 · 15 citations · Cited by this paper
  31. An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease · Sheila Dakhel Plaza · 2021 · 14 citations · Cited by this paper
  32. Evaluation of EDB Fibronectin in Plasma, Patient-Derived Xenograft Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tumor Tissues Using Immunoaffinity LC-MS/MS · Fengping Li · 2022 · 10 citations · Cited by this paper
  33. A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers · Richard T. Kenney · 2024 · 7 citations · Cited by this paper
  34. Untitled · Cited by this paper

Source: OpenAlex (CC0)